Acute Mesenteric IschemiaAMESIradiolNCT06445660
The Feasibility of a Radiological Score Based on CT Signs for Recognizing Salvageable Bowel in Acute Mesenteric Ischemia
An observational study of Acute Mesenteric Ischemia, run by University of Tartu at 1 site in Estonia.
Trial summary
Computed tomography (CT) is the standard modality for scanning patients with critical acute abdominal conditions, including suspected acute mesenteric ischemia (AMI). CT imaging can potentially differentiate between reversible and irreversible ischaemic damage of the bowel. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Mesenteric Ischemia
- How many people
- 157 participants
- Where
- 1 siteEstonia
- Study dates
- 6 Jun 2022to 31 Mar 2026
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This is a substudy of the AMESI study - "Incidence, Diagnosis, Management, and Outcome of Acute Mesenteric Ischaemia: A Prospective, Multicentre Observational Study." (Clinical Trials: NCT05218863) As of the end of August 2023, a total of 705 patients from 32 study sites worldwide have been enrolled, with 418 of them having confirmed cases of AMI. For patients with confirmed AMI, comprehensive data collection concerning diagnostics, management, and long-term outcomes has been completed
Who may be able to join
- Participant in AMESI study
- confirmed or suspected acute mesenteric ischaemia
- CT scan of the entire abdominal cavity / full body using intravenous contrast media is available
Who cannot join
- Scans without the use of an intravenous contrast media or those covering only a partial area of the abdomen will be excluded.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Feasibility of a Radiological Score Based on Quantified Analysis of Computed Tomography Signs for Recognizing Salvageable Bowel in Acute Mesenteric Ischemia: A Retrospective Analysis of Prospective Study
Computed tomography (CT) is the standard modality for scanning patients with critical acute abdominal conditions, including suspected acute mesenteric ischemia (AMI). CT imaging can potentially differentiate between reversible and irreversible ischaemic damage of the bowel. This moment is pivotal in selecting the treatment strategy for AMI - in the absence of irreversible damage; reperfusion therapy can preserve intestinal viability, thereby avoiding the need for bowel resection. The present study tests the hypothesis that combining several symptoms may enhance the diagnostic performance of CT scanning in detecting salvageable bowel in patients with AMI. This study is an ancillary component of the AMESI study (Clinical Trials: NCT05218863) - a prospective, multicentre observational study aimed at identifying the incidence and describing the outcomes of acute mesenteric ischemia (AMI) in adult hospitalized patients. The ultimate purpose of the present study is to create a computed tomography-based radiological score for the assessment of bowel viability in patients with AMI.
- Conditions
- Acute Mesenteric Ischemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Controls | Patients included in the AMESI study as suspected AMI | |
| AMI patients with salvageable bowel | Patients included in the AMESI study with confirmed AMI, who did not undergo bowel resection Patients with one of the following: 1. treated endovascularly and did not undergo bowel resection secondarily 2. received surgical revascularization without bowel resection (initial or secondary) 3. received explorative laparoscopy or laparotomy without the need for bowel resection (initially or secondarily) 4. received conservative treatment without the need for secondary bowel resection | |
| AMI patients with non-salvageable bowel | Patients included in the AMESI study with confirmed AMI who (one of the following): 1. underwent bowel resection initially 2. underwent bowel resection secondarily 3. did not undergo bowel resection because non-salvageable bowel 4. were changed to palliation due to the progression of ischaemia after any initial treatment with curative intention (including endovascular and conservative) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Frequency rate
Frequency rate of common radiological signs in AMI patients with and without salvageable bowel.
Measured: up to one month
Secondary outcomes (1)
Performance of the radiological score
Performance of the radiological score in patients with different types of AMI.
Measured: up to one month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jun 2024
- Study start6 Jun 2022
- Primary completion5 Apr 2023
- Study completion31 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Acute Mesenteric IschemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 157 participants (actual)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- University of Tartu
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Annika Reintam Blaser, University of Tartu
- Investigators
- Joel Starkopf, Study chair, University of Tartu, Department of Anaesthesiology and Intensive Care
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06445660
- Sponsor's protocol ID
- 03.01.2024
- Acronym
- AMESIradiol
- Status last verified
- Nov 2026
- First submitted
- 22 May 2024
- Last updated
- 6 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Reim M, Koitmae M, Bala M, Biloslavo A, Casian D, Zakaria AD, Fuglseth H, Geck M, Gibello L, Itzhaki MH, Hess B, Kase K, Malcova T, Murruste M, Nedredal GI, Ismail MIS, Talving P, Tamme K, Vetrhus M, Visconti D, Valk K, Starkopf J, Blaser AR. CT-based radiological score (AMESI CT-score) for severity of bowel injury in acute mesenteric ischemia. Abdom Radiol (NY). 2026 Aug 28. doi: 10.1007/s00261-026-05743-3. Online ahead of print.
PubMed 42660990
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Feasibility of a Radiological Score Based on Quantified Analysis of Computed Tomography Signs for Recognizing Salvageable Bowel in Acute Mesenteric Ischemia: A Retrospective Analysis of Prospective Study
- ClinicalTrials.gov ID
- NCT06445660
- Acronym / sponsor ID
- AMESIradiol / 03.01.2024
- Conditions
- Acute Mesenteric Ischemia
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 157 participants (actual)
- Lead sponsor
- University of TartuUniversity, hospital or other
- Study start
- 6 Jun 2022 (actual)
- Primary completion
- 5 Apr 2023 (actual)
- Study completion
- 31 Mar 2026 (actual)
- First posted
- 6 Jun 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Computed tomography (CT) is the standard modality for scanning patients with critical acute abdominal conditions, including suspected acute mesenteric ischemia (AMI). CT imaging can potentially differentiate between reversible and irreversible ischaemic damage of the bowel. This moment is pivotal in selecting the treatment strategy for AMI - in the absence of irreversible damage; reperfusion therapy can preserve intestinal viability, thereby avoiding the need for bowel resection. The present study tests the hypothesis that combining several symptoms may enhance the diagnostic performance of CT scanning in detecting salvageable bowel in patients with AMI. This study is an ancillary component of the AMESI study (Clinical Trials: NCT05218863) - a prospective, multicentre observational study aimed at identifying the incidence and describing the outcomes of acute mesenteric ischemia (AMI) in adult hospitalized patients. The ultimate purpose of the present study is to create a computed tomography-based radiological score for the assessment of bowel viability in patients with AMI.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Year
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Controls | – | –Patients included in the AMESI study as suspected AMI |
| AMI patients with salvageable bowel | – | –Patients included in the AMESI study with confirmed AMI, who did not undergo bowel resection Patients with one of the following: 1. treated endovascularly and did not undergo bowel resection secondarily 2. received surgical revascularization without bowel resection (initial or secondary) 3. received explorative laparoscopy or laparotomy without the need for bowel resection (initially or secondarily) 4. received conservative treatment without the need for secondary bowel resection |
| AMI patients with non-salvageable bowel | – | –Patients included in the AMESI study with confirmed AMI who (one of the following): 1. underwent bowel resection initially 2. underwent bowel resection secondarily 3. did not undergo bowel resection because non-salvageable bowel 4. were changed to palliation due to the progression of ischaemia after any initial treatment with curative intention (including endovascular and conservative) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This is a substudy of the AMESI study - "Incidence, Diagnosis, Management, and Outcome of Acute Mesenteric Ischaemia: A Prospective, Multicentre Observational Study." (Clinical Trials: NCT05218863) As of the end of August 2023, a total of 705 patients from 32 study sites worldwide have been enrolled, with 418 of them having confirmed cases of AMI. For patients with confirmed AMI, comprehensive data collection concerning diagnostics, management, and long-term outcomes has been completed
Key inclusion criteria (3 listed)
- Participant in AMESI study
- confirmed or suspected acute mesenteric ischaemia
- CT scan of the entire abdominal cavity / full body using intravenous contrast media is available
Key exclusion criteria (1 listed)
- Scans without the use of an intravenous contrast media or those covering only a partial area of the abdomen will be excluded.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Frequency rate
Time frame: up to one month
Frequency rate of common radiological signs in AMI patients with and without salvageable bowel.
1 secondary outcome
Performance of the radiological score
Time frame: up to one month
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
- Background: PubMed 42660990Reim M, Koitmae M, Bala M, Biloslavo A, Casian D, Zakaria AD, Fuglseth H, Geck M, Gibello L, Itzhaki MH, Hess B, Kase K, Malcova T, Murruste M, Nedredal GI, Ismail MIS, Talving P, Tamme K, Vetrhus M, Visconti D, Valk K, Starkopf J, Blaser AR. CT-based radiological score (AMESI CT-score) for severity of bowel injury in acute mesenteric ischemia. Abdom Radiol (NY). 2026 Aug 28. doi: 10.1007/s00261-026-05743-3. Online ahead of print.
- Individual participant dataSharing planned: Undecided
Related trials for Acute Mesenteric Ischemia
Recruiting
Evaluation of the Discriminative Abilities of Biomarkers for the Diagnosis of Acute Mesenteric Ischemia Compared With Another Similar Clinical Presentation: a Pilot Study
Acute Mesenteric Ischemia
Active, not recruiting
ThromBus Aspiration for Acute Mesenteric Artery Occlusion With Emergent Laparoscopic Surgery
Acute Mesenteric Ischemia
RecruitingObservational study
Predictors of Transmural Non-Occlusive Mesenteric Ischemia in ICU Patients With Suspected Acute Mesenteric Ischemia
Non-Occlusive Mesenteric Ischaemia (NOMI), Acute Mesenteric Ischemia
RecruitingObservational study
Assessment of Quality of Life After Acute Mesenteric Ischemia
Acute Mesenteric Ischemia
Recruiting
Searching Biomarkers of Acute Intestinal Ischemic Injuries
Acute Mesenteric Ischemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Joel Starkopf study chair
University of Tartu, Department of Anaesthesiology and Intensive Care
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Mesenteric Ischemia, run by University of Tartu at 1 site in Estonia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Estonia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Frequency rate (time frame: up to one month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06445660, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.